Fight Against Coronavirus: Nexcelom China Team Provides Assay Development Support to Scientists
Our team of field application scientists have been providing assay development support to scientists in State Key Laboratory of Respiratory Diseases in China, for the screening of antiviral agents against SARS-CoV-2 virus, the cause of COVID-19. The researchers are using the Celigo Image Cytometry system to screen drug candidates and assess their efficacy.
The image above shows, in green, infected Vero E6 cells as well as DAPI stained cellular nuclei. Post image capture the images were analyzed using the Celigo built-in gating interphase.
The following steps were used to image the cells:
Vero E6 cells were infected by wild type SARS-CoV-2 for 24 h (handled in BLS3 lab)
Drug serial dilutions were added before, during, and after infection
Viral proteins were stained with AF488 and cellular nuclei were stained with DAPI
The stained 96-well plate was imaged and analyzed on the Celigo.
For each well, number of infected cells and total cells were counted by the Celigo® Plate Imager. Infectivity was calculated for each condition automatically.
Since 2017, Nexcelom has been collaborating with leading virology labs: Vaccine Research Center, Institute of Allergy and Infectious Diseases, the Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH), to advance viral research and development.